{"preliminary_commentary":{"by_channel":{"bluesky_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT04849910","nct_id":"NCT04849910","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04849910. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"VOR33 infusion followed by Mylotarg Dose Level 1","label":"Cohort 1","type":"EXPERIMENTAL"},{"description":"VOR33 infusion followed by Mylotarg Dose Level 2","label":"Cohort 2","type":"EXPERIMENTAL"},{"description":"VOR33 infusion followed by Mylotarg Dose Level 3","label":"Cohort 3","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-05-28","type":"ACTUAL"},"conditions":["Leukemia, Myeloid, Acute","Myelodysplastic Syndromes"],"enrollment":{"count":67,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"VOR33","otherNames":[],"type":"BIOLOGICAL"},{"name":"Mylotarg","otherNames":["gemtuzumab ozogamicin"],"type":"DRUG"}],"last_update":"2025-07-29","lead_sponsor":"Vor Biopharma","official_title":"A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients With Acute Myeloid Leukemia Who Are at High-Risk for Leukemia Relapse Following Hematopoietic Cell Transplantation","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2025-05-28","type":"ACTUAL"},"primary_outcomes":[{"measure":"Incidence of neutrophil engraftment","timeFrame":"Day 28"}],"references":[{"citation":"DiPersio JF, Koehne G, Shah NN, Bernard L, Suh HC, Koura D, Tamari R, Mushtaq MU, Maakaron J, Rimando J, Kennedy VE, Patel SS, Hudson C, Loken MR, Slapak CA, Lloyd DM, Stanizzi DA, Lee-Sundlov MM, Thosar S, Mundelboim G, Guo G, Ge HG, Li BE, Xavier-Ferrucio J, Hyzy SL, Lin MI, Raffel GD, Cooper BW. CRISPR-Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial. Nat Med. 2026 May;32(5):1763-1772. doi: 10.1038/s41591-026-04362-1. Epub 2026 May 12.","pmid":"42120728","type":"DERIVED"},{"citation":"Lydeard JR, Lin MI, Ge HG, Halfond A, Wang S, Jones MB, Etchin J, Angelini G, Xavier-Ferrucio J, Lisle J, Salvadore K, Keschner Y, Mager H, Scherer J, Hu J, Mukherjee S, Chakraborty T. Development of a gene edited next-generation hematopoietic cell transplant to enable acute myeloid leukemia treatment by solving off-tumor toxicity. Mol Ther Methods Clin Dev. 2023 Oct 13;31:101135. doi: 10.1016/j.omtm.2023.101135. eCollection 2023 Dec 14.","pmid":"38027064","type":"DERIVED"}],"start_date":{"date":"2021-12-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS","url":"https://clinicaltrials.gov/study/NCT04849910"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04849910"}